All companies › ELVN

ELVN · Enliven Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells7
Research cases0
Last filing2026-10-01

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-17 — Collins Helen Louise · sold 1,844 @ $50.71 2026-09-17 — Collins Helen Louise · sold 240 @ $51.48 2026-09-17 — Collins Helen Louise · sold 2,916 @ $50.03 2026-09-17 — Hohl Benjamin · sold 2,194 @ $50.72 2026-09-17 — Hohl Benjamin · sold 289 @ $51.49 2026-09-17 — Hohl Benjamin · sold 3,535 @ $50.03 2026-10-01 — Garland J. Scott · sold 13,000 @ $46.67
2026-09-172026-10-01

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Collins Helen Louise CHIEF MEDICAL OFFICER
Hohl Benjamin CHIEF FINANCIAL OFFICER
Garland J. Scott Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $ELVN is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-01', 'insider_name': 'Garland J. Scott', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 13000.0, 'price': 46.6707, 'value': 606719.1, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Collins Helen Louise', 'insider_title': 'CHIEF MEDICAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 1844.0, 'price': 50.71, 'value': 93509.24, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Collins Helen Louise', 'insider_title': 'CHIEF MEDICAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 240.0, 'price': 51.48, 'value': 12355.2, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Collins Helen Louise', 'insider_title': 'CHIEF MEDICAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 2916.0, 'price': 50.03, 'value': 145887.48, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Hohl Benjamin', 'insider_title': 'CHIEF FINANCIAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 2194.0, 'price': 50.72, 'value': 111279.68, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Hohl Benjamin', 'insider_title': 'CHIEF FINANCIAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 289.0, 'price': 51.49, 'value': 14880.61, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Hohl Benjamin', 'insider_title': 'CHIEF FINANCIAL OFFICER', 'transaction_type': 'Open-market sell', 'shares': 3535.0, 'price': 50.03, 'value': 176856.05, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for ELVN today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.